ENDRA Life Sciences Strengthens Intellectual Property with Issuance of Five New International Patents
May 02 2024 - 8:00AM
Business Wire
ENDRA’s IP Portfolio Reaches Milestone of 80
Issued Patents
ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of
Thermo Acoustic Enhanced UltraSound (TAEUS®), announces the
issuance of five new patents, including three in Europe and two in
China. ENDRA’s intellectual property (IP) portfolio now includes 80
issued patents worldwide, providing protection for the TAEUS system
with its novel thermoacoustic technology.
"With the issuance of these five patents, we've reached a
significant milestone of 80 global patents," said Francois
Michelon, ENDRA's Chairman and CEO. "Our extensive IP portfolio
safeguards and sets apart ENDRA’s thermoacoustic technology in
areas of high unmet clinical need. We're actively enhancing our
intellectual property to secure our technology in key global
markets and exploring licensing opportunities for indications
beyond our core focus, opening further growth avenues for the
company."
The following five patents were issued:
- European Patent No. EP4051151 (the ‘151 patent), titled “Radio
Frequency Applicator and Thermoacoustic Imaging System Employing
the Same,” covers a radio frequency (RF) applicator device and
system for providing reliable RF energy to a target area of tissue.
Specifically, the '151 patent structurally defines ENDRA's
innovative solution to providing RF energy to targeted tissue
regions for applications, such as liver fat quantification.
- European Patent No. EP4037554, titled “Method and System for
Determining a Material Type of an Object of Interest,” protects
ENDRA's method and system for determining a material type by
utilizing TAEUS. The patent has potential application beyond liver
measurements, which may include outside the human body.
- European Patent No. EP4037551 (the ‘551 patent), titled “Method
and System for Determining a Parameter of a Material of Interest,”
relates to a novel method for determining at least one parameter of
interest of a material utilizing TAEUS. Examples of potential
parameters of interest include the Grüneisen parameter, which is
the ratio of thermal pressure to thermal energy and conductivity.
In addition, the ‘551 patent expands the imaging potential for the
TAEUS technology outside the human body for select applications,
such as material testing and identification.
- The Chinese National Intellectual Property Administration
issued ENDRA two new patents, ZL2019800868227 (the ‘227 patent) and
ZL202110813939X (the ‘39X patent), both titled “Method and System
for Monitoring Tissue Temperature.” The ‘227 and ‘39X patents
relate to novel methods and systems for monitoring tissue
temperature with TAEUS during surgical procedures, such as
thermotherapy and cryotherapy.
About ENDRA Life Sciences Inc.
ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced
UltraSound (TAEUS®), a ground-breaking technology that
characterizes tissue like MRI, but at 1/40th the cost and at the
point of patient care. TAEUS® is designed to work in concert with
over 700,000 ultrasound systems in use globally today. TAEUS® is
initially focused on the measurement of fat in the liver as a means
to assess and monitor Steatotic Liver Disease (SLD) (formerly known
as NAFLD-NASH), a chronic liver spectrum that affects over two
billion people globally, and for which there are no practical
diagnostic tools. Beyond the liver, ENDRA is exploring several
other clinical applications of TAEUS®, including tissue temperature
imaging during energy-based surgical procedures. For information,
please visit www.endrainc.com.
Forward-Looking Statements
All statements in this press release that are not based on
historical fact are “forward-looking statements” within the meaning
of Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. Forward-looking statements, which
are based on certain assumptions and describe our future plans,
strategies and expectations, can generally be identified by the use
of terms such as “approximate,” “anticipate,” “attempt,” “believe,”
“could,” “estimate,” “expect,” “forecast,” “future,” “goal,”
“hope,” “intend,” “may,” “plan,” “possible,” “potential,”
“project,” “seek,” “should,” “will,” “would,” or other comparable
terms (including the negative of any of the foregoing), although
some forward-looking statements are expressed differently. Examples
of forward-looking statements for ENDRA include, among others:
estimates of the timing of future events and anticipated results of
its development efforts, including the timing of submission for and
receipt of required regulatory approvals and product launches and
sales; statements relating to future financial position and
projected costs and revenue; expectations concerning ENDRA’s
business strategy; and statements regarding ENDRA’s ability to find
and maintain development partners. Forward-looking statements
involve inherent risks and uncertainties that could cause actual
results to differ materially from those in the forward-looking
statements as a result of various factors including, among others:
the ability to raise additional capital in order to continue as a
going concern; the ability to obtain regulatory approvals necessary
to sell ENDRA medical devices in certain markets in a timely
manner, or at all; the ability to develop a commercially feasible
technology and its dependence on third parties to design and
manufacture its products; ENDRA’s ability to maintain compliance
with Nasdaq listing standards; ENDRA’s dependence on its senior
management team; the ability to find and maintain development
partners; market acceptance of ENDRA’s technology and the amount
and nature of competition in its industry; ENDRA’s ability to
protect its intellectual property; and the other risks and
uncertainties described in the Risk Factors and Management’s
Discussion and Analysis of Financial Condition and Results of
Operations sections of the Company’s most recent Annual Report on
Form 10-K and in subsequent Quarterly Reports on Form 10-Q filed
with the SEC. You should not rely upon forward-looking statements
as predictions of future events. The forward-looking statements
made in this press release speak only as of the date of issuance,
and ENDRA assumes no obligation to update any such forward-looking
statements to reflect actual results or changes in expectations,
except as otherwise required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240426475764/en/
Company Contact: Irina Pestrikova Senior Director,
Finance investors@endrainc.com www.endrainc.com
Investor Relations Contact: Yvonne Briggs LHA Investor
Relations (310) 691-7100 ybriggs@lhai.com
ENDRA Life Sciences (NASDAQ:NDRA)
Historical Stock Chart
From Jul 2024 to Aug 2024
ENDRA Life Sciences (NASDAQ:NDRA)
Historical Stock Chart
From Aug 2023 to Aug 2024